Cantargia’s Rights Offering

Vinge advised Cantargia on the deal. Cantargia AB (publ) secured a rights offering of approximately SEK 170 million. Cantargia develops antibody based therapies against the target...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

SAS’ Reconstruction Proceedings

Vinge advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission,...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Active Biotech’s Rights Offering

Vinge advised Active Biotech on the offering. Active Biotech AB (publ) (Nasdaq Stockholm) has carried out a rights issue of approximately SEK 51 million. Active Biotech...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Cantargia’s Shares Offering

Vinge advised Cantargia AB on the deal. Cantargia AB (publ) completed a directed share issue of approximately SEK 59 million (approx. $5.4 million) to a number of...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Dustin’s Rights Offering

Vinge advised Axel Johnson on offering. Dustin AB (publ) carries out a rights offering of approximately SEK 1,750 million (approx. $160 million), fully guaranteed by Axel...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here